The US Biosimilars Act: Challenges Facing Regulatory Approval

Author： Nick Cecil  

Publisher： Adis International

ISSN： 1178-2595

Source： Pharmaceutical Medicine, Vol.26, Iss.3, 2012-06, pp. : 145-152

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biosimilars: Current Scientific and Regulatory Considerations

By  

Current Clinical Pharmacology, Vol. 9, Iss. 1, 2014-02 ,pp. : 53-63

Bentham Science Publishers

Access to resources Recommend Favorite

Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities

By  

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 2, Iss. 3, 2015-12 ,pp. : 158-164

Bentham Science Publishers

Access to resources Recommend Favorite

Biosimilars

By  

Pharmazie in unserer Zeit, Vol. 41, Iss. 6, 2012-11 ,pp. : 437-437

Blackwell Publishing

Access to resources Recommend Favorite

Post-Approval Changes in Pharmaceuticals: Regulatory Perspectives in Europe

By  

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 2, Iss. 2, 2015-08 ,pp. : 60-68

Bentham Science Publishers

Access to resources Recommend Favorite

Biosimilars of Biological Drug Therapies: Regulatory, Clinical and Commercial Considerations

By Dranitsaris George  

Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. : 1527-1536

Adis International

Access to resources Recommend Favorite